LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. (LMAT) Financial Performance & Income Statement Overview
Review LeMaitre Vascular, Inc. (LMAT) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
LeMaitre Vascular, Inc. (LMAT) Income Statement & Financial Overview
Explore comprehensive income reports for LeMaitre Vascular, Inc. LMAT, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $59.87M | $55.72M | $54.82M | $55.85M |
| Cost of Revenue | $18.45M | $17.13M | $17.64M | $17.38M |
| Gross Profit | $41.42M | $38.59M | $37.18M | $38.47M |
| Gross Profit Ratio | $0.69 | $0.69 | $0.68 | $0.69 |
| R&D Expenses | $4.09M | $3.62M | $3.66M | $4.28M |
| SG&A Expenses | $24.70M | $22.12M | $20.37M | $19.80M |
| Operating Expenses | $28.79M | $25.74M | $24.03M | $24.09M |
| Total Costs & Expenses | $47.24M | $42.86M | $41.67M | $41.47M |
| Interest Income | $2.90M | $1.61M | $1.20M | $1.14M |
| Interest Expense | $1.29M | $205000.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $2.55M | $2.42M | $2.43M | $2.38M |
| EBITDA | $12.63M | $16.64M | $15.57M | $16.76M |
| EBITDA Ratio | $0.21 | $0.30 | $0.28 | $0.30 |
| Operating Income | $12.63M | $12.85M | $13.15M | $14.38M |
| Operating Income Ratio | $0.21 | $0.23 | $0.24 | $0.26 |
| Other Income/Expenses (Net) | $1.61M | $1.17M | $1.40M | $1.13M |
| Income Before Tax | $14.24M | $14.02M | $14.55M | $15.51M |
| Income Before Tax Ratio | $0.24 | $0.25 | $0.27 | $0.28 |
| Income Tax Expense | $3.23M | $2.84M | $3.41M | $3.68M |
| Net Income | $11.01M | $11.18M | $11.14M | $11.83M |
| Net Income Ratio | $0.18 | $0.20 | $0.20 | $0.21 |
| EPS | $0.49 | $0.50 | $0.50 | $0.53 |
| Diluted EPS | $0.48 | $0.49 | $0.49 | $0.52 |
| Weighted Avg Shares Outstanding | $22.57M | $22.51M | $22.48M | $22.46M |
| Weighted Avg Shares Outstanding (Diluted) | $22.90M | $22.90M | $22.84M | $22.73M |
Over the past four quarters, LeMaitre Vascular, Inc. demonstrated steady revenue growth, increasing from $55.85M in Q2 2024 to $59.87M in Q1 2025. Operating income reached $12.63M in Q1 2025, maintaining a consistent 21% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $12.63M, reflecting operational efficiency. Net income dropped to $11.01M, with EPS at $0.49. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan